罗格列酮辅助治疗特发性肺纤维化患者的临床效果观察

目的 观察罗格列酮辅助治疗对肺纤维化患者的临床效果。 方法 筛选2013-2014年期间已确诊的肺纤维化患者60例,随机分为两组,A组为罗格列酮治疗组,在常规治疗的基础上口服罗格列酮;B组为常规治疗组。观察患者症状改善情况、胸部影像学、动脉血气和肺功能等。 结果 治疗后,A组总有效率为53.33%,B组总有效率为43.33%,两组差异有统计学意义(P<0.05);两组的临床症状积分,TCL、FVC和DLCO等肺功能指标,PaCO₂、PaO₂等动脉血气指标均优于治疗前,差异均有统计学意义(P<0.05);且治疗后A组各项指标均优于B组,差异有统计学意义(P<0.05)。 结论 罗格列酮辅助治疗可以改善患者的临床症状、肺功能和血气情况,提高患者的生活质量。

Observation of therapeutic effect of rosiglitazone in treatment of idiopathic pulmonary fibrosis

Objective To observe the clinical effect of rosiglitazone in treatment of patients with idiopathic pulmonary fibrosis. Methods Totally 60 patients with idiopathic pulmonary fibrosis from 2013 to 2014 were randomly divided into two groups, i.e., the conventional treatment group and the conventional plus rosiglitazone treatment group. The records of symptom, the examination of chest radiograph, blood gas analysis and pulmonary function were made. Results A total effective rate was 53.33% in the rosiglitazone treated group while 43.33% in the conventional group(P<0.05). The clinical symptom score; the lung function indicators, such as TCL, FVC and DLCO; the arterial blood gas indicators such as PaCO₂ and PaO₂ showed that the patients had significant improvement after treatment (P<0.05)and the patients in the rosiglitazone treated group improved much better than the patients in the conventional group(P<0.05). Conclusion Adjuvant therapy with rosiglitazone can improve the clinical symptoms, lung function, indicators of blood gas analysis and the quality of life of such patients.